Abstract
BackgroundCure rates for Hodgkin’s lymphoma are excellent, but excess short-term and long-term morbidities from treatment remain a concern. Immunotherapy targeting both tumor antigens and the immunosuppressive tumor microenvironment in children,...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have